Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Scand J Rheumatol ; 47(4): 311-318, 2018 07.
Article in English | MEDLINE | ID: mdl-29409385

ABSTRACT

OBJECTIVES: Iloprost plays an important role in the treatment of Raynaud's phenomenon (RP), but has transient vasodilatory effects owing to its very short half-time. We aimed to evaluate short- and medium-term haemodynamic effects of iloprost by measuring dorsal finger microvessel blood flow using laser Doppler flowmetry (LDF), in patients with RP associated with systemic sclerosis (SSc). METHOD: In 24 consecutive SSc patients with RP (disease duration 10.5 ± 1.3 years), LDF with heating probes was used to measure blood flow in four fingers by occlusive and heating tests, at baseline, after 3 consecutive days of iloprost infusion, and at 24 h and 7 days after last iloprost infusion. Nailfold videocapillaroscopy (NVC) patterns of microvascular damage were investigated. Sixteen healthy controls were studied to compare baseline flows. RESULTS: Compared to controls, SSc patients showed significantly impaired axon reflex vasoregulation and nitric oxide responses at baseline (p = 0.001 and p = 0.03, respectively). After iloprost, a prompt but transient significant improvement in endothelial-dependent vasodilation (occlusive test) was seen only in SSc patients with an 'active' NVC pattern (p ≤ 0.05). The iloprost effects vanished within 7 days after the last infusion. No significant differences were found, in the whole study, between patients with and without digital ulcers. CONCLUSIONS: Microcirculatory blood flow increases following 3 days of iloprost infusion but fades shortly after treatment. Although iloprost is effective in reducing the severity of RP in SSc, the most suitable regimen and timing to obtain longer lasting vasodilatory benefits remain to be established.


Subject(s)
Fingers/blood supply , Iloprost/pharmacology , Microcirculation/drug effects , Regional Blood Flow/drug effects , Scleroderma, Systemic/drug therapy , Vasodilation/drug effects , Vasodilator Agents/pharmacology , Adult , Aged , Case-Control Studies , Female , Fingers/diagnostic imaging , Humans , Iloprost/therapeutic use , Infusions, Intravenous , Laser-Doppler Flowmetry , Longitudinal Studies , Male , Microscopic Angioscopy , Middle Aged , Scleroderma, Systemic/physiopathology , Vasodilator Agents/therapeutic use
2.
Ann Rheum Dis ; 69(1): 218-21, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19279015

ABSTRACT

OBJECTIVES: To measure the prevalence of, and factors associated with, left ventricular (LV) dysfunction in systemic sclerosis (SSc). METHODS: The EUSTAR database was first searched. A case-control study of a patient subset was then performed to further identify independent factors associated with LV dysfunction by simple and multiple regression. RESULTS: Of 7073 patients, 383 (5.4%) had an LV ejection fraction (EF) of <55%. By multiple regression analysis, age, sex, diffuse cutaneous disease, disease duration, digital ulcerations, renal and muscle involvement, disease activity score, pulmonary fibrosis and pulmonary arterial hypertension were associated with LV dysfunction. In the second phase, 129 patients with SSc with LVEF <55% were compared with 256 patients with SSc with normal LVEF. Male sex (OR 3.48; 95% CI 1.74 to 6.98), age (OR 1.03; 95% CI 1.01 to 1.06), digital ulcerations (OR 1.91; 95% CI 1.05 to 3.50), myositis (OR 2.88; 95% CI 1.15 to 7.19) and use of calcium channel blockers (OR 0.41; 95% CI 0.22 to 0.74) were independent factors associated with LV dysfunction. CONCLUSION: The prevalence of LV dysfunction in SSc is 5.4%. Age, male gender, digital ulcerations, myositis and lung involvement are independently associated with an increased prevalence of LV dysfunction. Conversely, the use of calcium channel blockers may be protective.


Subject(s)
Scleroderma, Systemic/complications , Ventricular Dysfunction, Left/etiology , Adult , Age Factors , Aged , Calcium Channel Blockers/therapeutic use , Epidemiologic Methods , Europe/epidemiology , Female , Fingers , Humans , Male , Middle Aged , Myositis/complications , Myositis/epidemiology , Scleroderma, Systemic/epidemiology , Sex Factors , Skin Ulcer/complications , Skin Ulcer/epidemiology , Stroke Volume , Ventricular Dysfunction, Left/epidemiology , Ventricular Dysfunction, Left/prevention & control
4.
Reumatismo ; 59(2): 135-9, 2007.
Article in Italian | MEDLINE | ID: mdl-17603693

ABSTRACT

In systemic sclerosis (SSc) occurrence of recurrent digital ulcers (DU) is cause of pain and functional disability of hands. Treatment with vasodilator agents, such as calcium channel blockers, ACE inhibitors, prostanoids, has not shown to be an effective therapy. There is evidence that endotelin-1 (ET-1) is a key mediator in regulation of vascular tone and its enhanced production in SSc is believed to lead to vasoconstriction, vessel remodelling, local ischemia and ulcers of fingertips. Recently, an oral endothelin receptor antagonist, bosentan, has been proved to be effective in the treatment of SSc associated pulmonar arterial hypertension (PAH) and to decrease the development of new DU in patients with SSc. In this study, we assessed the occurrence of new DU in eight patients with SSc associated PAH and one SSc patient with recurrent DU refractory to standard vasodilatation therapy. All patients received bosentan at dosage of 62.5 mg bid for 4 weeks and 125 mg bid thereafter for one year. All patients had 3-4 DU of hands at baseline and one patients had also ulcers at lower limbs. In seven out of nine patients we did not record the occurrence of new DU and we also observed a 50% reduction of existing DU, whereas new DU occurred only in two patients. These data suggest that ET-1 plays a key role in DU induction in SSc patients and that ET-1 inhibition by bosentan can be an effective therapeutic strategy.


Subject(s)
Endothelin A Receptor Antagonists , Hand Dermatoses/drug therapy , Hand Dermatoses/etiology , Scleroderma, Systemic/complications , Skin Ulcer/drug therapy , Skin Ulcer/etiology , Sulfonamides/therapeutic use , Aged , Bosentan , Female , Fingers , Humans , Male , Middle Aged
5.
Reumatismo ; 59(1): 20-4, 2007.
Article in Italian | MEDLINE | ID: mdl-17435838

ABSTRACT

Joint involvement in systemic sclerosis (SSc) commonly occurs as arthralgias, while a true arthritis is less frequent. The most common arthritis developing in SSc is rheumatoid arthritis (RA) and its diagnosis may be misled by concomitant joint contracture or tendon sheath involvement due to SSc. Anti-citrullinated cyclic peptide (CCP) antibodies are an emerging tool to diagnose RA and have shown to be more specific than rheumatoid factor. We assessed the prevalence of anti-CCP antibodies in SSc patients and evaluated their sensitivity and specificity for associated RA. Searching for RF and anti-CCP antibodies and joint examination were carried out in sixty consecutive SSc patients. Hands and feet standard x-rays were performed in patients complaining with arthralgia and/or arthritis. Six out of sixty (10%) SSc patients had RA according to 1987 ARA revised criteria. Anti-CCP were detected in 5 patients (sensitivity 83%) and RF was present in all RA patients (sensitivity 100%). However, anti-CCP antibodies had a much higher specificity (94%) than RF (41%) for RA. Our study suggests that anti-CCP antibodies are a useful test to identify patients with SSc having also RA. This is crucial in the management of SSc because may allow an adequate therapy of RA and prevent further joint damage in patients who already have a poor quality of life.


Subject(s)
Autoantibodies/blood , Peptides, Cyclic/immunology , Scleroderma, Systemic/immunology , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/immunology , Biomarkers/blood , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...